
Polatuzumab vedotin-piiq plus R-CHP can reduce the need for any subsequent lines of therapy for patients with diffuse large B-cell lymphoma, according to an expert from The University of Texas MD Anderson Cancer Center.

Your AI-Trained Oncology Knowledge Connection!


Polatuzumab vedotin-piiq plus R-CHP can reduce the need for any subsequent lines of therapy for patients with diffuse large B-cell lymphoma, according to an expert from The University of Texas MD Anderson Cancer Center.

Geriatric assessments have now been recommended as part of the standard evaluation of an older adult considering cancer therapy.

Published: November 14th 2019 | Updated:

Published: April 19th 2023 | Updated: